Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
Triple-negative breast cancer has few treatment options. Promising results from recent clinical trials of immunotherapy combined with chemotherapy in patients with metastatic disease may soon change the way this aggressive cancer is treated. Just after this article was written, the FDA approved this combination for patients with triple-negative breast cancer.
After many years in development, the newest type of immunotherapy known as CAR T-cell therapy (or gene therapy) is becoming a mainstream treatment in some types of blood cancer, specifically in leukemia and lymphoma.
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Patients who are receiving immunotherapy should consult with their doctor immediately if and when any side effects occur, because immune-related adverse events may occur during therapy or even after discontinuation of therapy.
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer.
Patients with cancer and cancer survivors often experience anxiety and depression, which are normal responses to a traumatic event such as a cancer diagnosis. Unfortunately, many patients and cancer survivors do not receive appropriate treatment when their symptoms of depression should be treated.
Cancer treatment is getting even more expensive than before, and paying for it is yet another serious issue that many patients with cancer face. Even for patients who have private insurance through their employer or through an individual plan, many patients today are expected to pay an increasing share of their care from their own pocket.
The year 2015 will go down in medical history as an exceptional moment in the progress made in multiple myeloma, with 4 new drugs having been approved by the FDA and 1 drug already in use for patients with advanced disease being approved for use in all patients, including those who were just diagnosed with the disease. Although no cure is available yet, these new drugs bring significant progress to the treatment of patients with multiple myeloma.
Chronic myeloid leukemia (CML) is a blood cancer that results from a genetic abnormality that causes the production of too many white blood cells in the bone marrow. However, CML is not a genetic disease that runs in families.
Last modified: August 14, 2017
Subscribe to CONQUER: the patient voice® magazine
Receive timely cancer news & updates, patient stories, and more.